What are the precautions for taking upadacitinib?

UpadacitinibIndicated for the treatment of moderately to severely active rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, nonradiographic axial spondyloarthritis with objective signs of swelling, moderate to severe ulcerative colitis, and moderate to severe Crohn's disease. Common side effects of upadacitinib include upper respiratory tract infection (common cold, sinus infection) nausea, cough, and fever. What are the precautions for taking Upadacitinib(Upadacitinib)?

1.Serious infections may occur. The most common serious infections with Upapatinib include pneumonia and cellulitis. Among opportunistic infections, tuberculosis, multiple cutaneous herpes zoster, oral/esophageal candidiasis and cryptococcosis have been seen with Upapatinib. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with upadacitinib. Interrupt upadacitinib if the patient develops a serious or opportunistic infection. Patients who develop a new infection during treatment with uppatinib should receive prompt and complete diagnostic testing as appropriate for immunocompromised patients, appropriate antimicrobial therapy should be initiated, the patient should be monitored closely, and uppatinib should be discontinued if the patient does not respond to antimicrobial therapy. Upadatinib can be resumed once the infection is controlled.

2.The probability of mortality. In a large randomized postmarketing safety study of another JAK inhibitor in RA patients aged 50 years and older with at least 1 cardiovascular risk factor, uptake of RA was observed Patients treated with n>JAKinhibitors had a higher rate of all-cause mortality (including sudden cardiovascular death) than patients treated with TNF blockers. Before initiating or continuing treatment with upadacitinib, consider the benefits and risks for the individual patient.

3. Malignant and lymphoproliferative diseases may occur. Malignancies, including lymphoma, have been observed in clinical trials of Upapatinib. Before initiating or continuing treatment with Upapatinib, consider the benefits and risks of the individual patient, especially patients with a known malignancy (other than successfully treated NMSC), patients who develop malignancy during treatment, and patients who are current or past smokers.

4.In another study targeting patients 50 years and olderRA< with at least one cardiovascular risk factor In a large randomized post-marketing safety study of JAKinhibitors in patients, a major risk of treatment with JAKinhibitors was observed Adverse cardiovascular events(MACE)Incidence(Defined as cardiovascular death, non-fatal myocardial infarction(MI)and nonfatal stroke)higher thanTNFblocker-treated patients. Before initiating or continuing treatment with upadacitinib, consider the benefits and risks in the individual patient, especially patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed of the symptoms of serious cardiovascular events and what to do if they occur. Patients who have had a myocardial infarction or stroke should stop taking upadacitinib.

5. Thrombus may occur. Use JAKinhibitors (includingRINVOQ) to treat Thrombosis, including deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis, occurs in patients treated for inflammatory diseases. If thrombotic symptoms occur, patients should discontinue upadacitinib and receive immediate evaluation and appropriate treatment. Avoid use of upadatinib in patients who may be at increased risk for thrombosis.

6.Allergic reactions may occur. In clinical trials, patients receiving upadacitinib experienced serious allergic reactions, such as anaphylaxis and angioedema. If a clinically significant allergic reaction occurs, upadatinib should be discontinued and appropriate therapy initiated.

7.Gastrointestinal perforation may occur. Promptly evaluate patients with new abdominal pain to allow early identification of gastrointestinal perforation.

8.Embryo-Fetal toxicity. Based on animal studies, upadatinib may cause harm to the fetus when taken by pregnant women. Administration of upadatinib to rats and rabbits during organogenesis resulted in increased fetal malformations. Verify pregnancy status in patients of childbearing potential before initiating treatment. Inform women of reproductive potential of the potential risks to the fetus and to use effective contraception during upadatinib treatment and for 4 weeks after the end of treatment. The retail price of Bangladesh Yaopin International Pharmaceutical15mg 30 tablets7 more than one hundred. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.